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Abstract
Women have a one in eight lifetime risk of developing breast cancer. Risk factors for breast
cancer include genetic predisposition, reproductive factors, environmental exposure and lifestyle.
Preventative measures for breast cancer currently include screening with mammography and the
promotion of a healthy lifestyle including maintaining a healthy body weight and reduction of
risk factors for other chronic diseases such as diabetes. This paper discusses the case report of
46-year-old women being seen for preoperative evaluation for meniscus repair surgery. This
patient has a family history of breast cancer and is taking the Non-steroidal anti-inflammatory
drug (NSAID) ibuprofen for pain control. A literature review of Pubmed and CINHAL explored
ties between the use of NSAIDs and breast cancer prevention. Insufficient data exists to
recommend using and NSAID for the reduction of breast cancer risk at this time, further studies
will be needed.
Keywords: Breast Cancer, Non-steroidal Anti-inflammatory Drug (NSAID)
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Background
This paper will discuss the case of T. Smith, a 46-year-old woman with a familial history
of breast cancer who is also taking a non-steroidal anti-inflammatory drug (NSAID) for pain
control. It will look at the effect of NSAID use in the reduction of risk of breast cancer. The
patient, T. Smith has multiple known risk factors. She has a familial history of breast cancer in
her mother and maternal grandmother, she is also obese and has a history of smoking.
T. Smith is currently up to date on her screenings including mammography. She does
understand the increased risk associated with familial diagnosis, obesity and tobacco
use. T.Smith is currently using the NSAID ibuprofen 600 mg three times daily for the treatment
of pain related to her knee injury. She is also taking acetaminophen 1000 mg three times daily
for pain control and aspirin 81mg to reduce the risk of ACS and stroke.
A review of the literature was done to determine if taking NSAIDs on a regular basis has
shown to provide a clinically significant reduction to the overall risk of breast cancer. If that is
the case it could be recommended that T. Smith continue taking her NSAID medication, or
change to another medication with the intent of reducing her risk of breast cancer.
Case Report
This case report looks at T. Smith, a 46 year-old women, who presents for a preoperative
exam prior to knee surgery to repair a meniscus tear in her right knee. Vital signs are as follows :
BP 136/88
lb.

HR 78

T 98.5F

SPo2 95%

Height 5ft 6 in

Weight 211

BMI 34
Her history of present illness includes a recent diagnosis of meniscal tear in the right

knee. This injury occurred after sustaining a fall approximately 6 months ago. She has surgery
scheduled to repair this injury in 1 month. She has been taking acetaminophen 1000 mg three
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times daily and ibuprofen 600 mg three times daily with some mild relief of symptoms noted.
Her symptoms are worse with ambulation, she describes the pain as constant and aching.
Her medical history includes hypertension, diabetes type II and hypothyroidism. T. Smith
is obese with a BMI of 34. She also has a history of squamous skin cancer on her neck. Her
surgical history includes a hysterectomy, cesarean section following two normal pregnancies and
a biopsy and resection of the area of squamous cell skin cancer on her neck.
T. Smith takes several medications. For her hypertension she is taking lisinopril 10 mg
daily. For diabetes she is taking metformin 1000 mg twice daily and Rybelsus 7 mg daily. She is
taking Synthroid 125 mg daily for her hypothyroidism. She takes Aspirin 81 mg once daily for
secondary prevention of ACS and stroke. Finally, she is taking acetaminophen 1000 mg three
times daily and ibuprofen 600 mg three times daily for knee pain.
Her family history includes hypertension, hyperlipidemia, prostate cancer and coronary
artery disease in her father. He had cardiac catheterization with stent placement at age 55, he is
living. In her mother there is a history of hypertension, breast cancer at 60 and obesity. Her
maternal grandmother has hypertension and breast cancer. In her Paternal grandfather there was
hypertension and melanoma and her paternal grandmother had a cerebral vascular accident at age
80. T. Smith does have two younger siblings who are both alive and well.
T. Smith works in education, she is married and has 2 children. She is current on her
vaccinations and did receive an influenza vaccination for this season. She has a 20 pack year
history of smoking but did quit several years ago. She does not vape and does not use smokeless
tobacco. She drinks alcohol socially, less than once weekly. She has no personal or family
history of complications with anesthesia. However, she is allergic to amoxicillin and morphine,
the reaction to these medications is unknown. When asked, she denies any history of bleeding or
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clotting disorders and denies any unusual bruising. She does endorse occasional shortness of
breath with exertion.
Her exam is mostly unremarkable. The is some pain with palpation and with flexion and
extension of her right knee. She is grossly neurologically intact with no obvious concerns for
difficult intubation. Cardiac and respiratory exams within normal limits.
During her exam some basic lab work was ordered and an EKG obtained. The metabolic
panel and complete blood count with differential were within normal limits. Her TSH was found
to be 3.65, also within normal limits. The EKG obtained was slightly concerning. There was
slight ST elevation noted in leads II, V4 and V5.
The patient states that she is up to date on all of her screenings including mammograms
and colonoscopy. Additional education was provided regarding the importance of continuing
these screenings as she is at increased risk for cancers due to family history and personal history
of smoking. Regarding the abnormal EKG, T. Smith will be sent for a stress test prior to
determining risk for surgery. Finally, the use of ibuprofen, ASA and diabetic medications prior
to surgery was discussed. She was given instructions to go to the emergency department with any
chest pain, shortness of breath or other symptoms concerning for ACS.
Literature Review
The first database used was Pubmed. This database looks at biomedical and life science
literature from a variety of sources. Pubmed is based out of the National Institute of Health’s
National Library of Medicine. Pubmed was accessed using the University of North Dakota
subscription. The search terms used for the initial search were “Breast Cancer” AND “ NSAID”.
Limits placed on this search included articles from 2015-2020. Articles were only considered if
they were looking at the adult population and were written in English. This search returned 291
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articles. After review, 9 pertinent articles were found. Using this search the articles about topics
associated with other uses for NSAIDs in breast cancer such as post-operative pain control were
kept to a minimum.
The Cumulative Index to Nursing and Health Literature (CINAHL) database was also
used, this data base was accessed using the University of North Dakota subscription. The search
terms used were “Breast Cancer” AND “NSAID”. This search found many articles that were
found using the previously mentioned database. Three additional, pertinent articles were found
for use in the literature review. The limits set for the search included the date published (20152020), articles were only considered if they were less than 5 years old, English language and
included an adult population.
The lifetime time risk of a woman developing breast cancer is 1 in 8 (approximately
13%) (Howlander et al., 2019). Modifiable risk factors for breast cancer reduction include
lifestyle such as exercise and environmental exposures like radiation, tobacco and alcohol. There
are also non-modifiable risks for breast cancer which include genetic predisposition and
reproductive factors like age of menarche, age of first pregnancy and breast feeding. (Hawk,
Maresso, & Brown, 2018). The following literature review looks at the effect of NSAIDs in the
prevention of breast cancer.
While experimental studies have shown some promise in using NSAIDs to protect
against breast cancer, epidemiologic studies have been less promising (Cairat et al.,
2019). NSAIDs work on cyclooxygenase enzymes (COX-1 and COX-2) by inhibiting their
activity. This inhibition allows for a reduction of inflammation and inhibition of platelet
aggregation. Like colorectal cancer, breast cancer has been shown to have over expression of
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COX-2. More research is needed to show a correlation between the use of NSAIDs and breast
cancer prevention (Hawk et al., 2018).
A European cohort study within the European Prospective Investigation into Cancer and
Nutrition (EPIC) (Cairat et al., 2019) used multiple models to show correlation between NSAID
use with a reduction in breast cancer rates. Self-reported information on NSAID use was
gathered in five of the countries part of the EPIC study. There were 140,981 women included in
the analysis. Of these women, 7% were regularly using NSAIDs at baseline. After a follow-up
period of 13 years, 7,379 cases of breast cancer were diagnosed. This study did not reveal a
significant, consistent link between the use of NSAIDs and a reduction in the rate of breast
cancer. This study did show a possible correlation between the use of hormone therapy and
NSAIDs in the development of cancer, however that correlation was not examined in this trial
(Cairat et al., 2019). Another study looked at a large cohort of Danish women diagnosed with
breast cancer. The study analyzed the use of NSAIDs in the reduction of contralateral breast
cancer. In this study there was no proof of a reduction of the rate of contralateral breast cancer in
those who took NSAIDs regardless of COX selectivity (Bens et al., 2018).
Several trials looked specifically at the use of NSAIDs in the prevention of breast cancers
that were hormone positive. The Spanish Multi-Case-Control study (Dierssen-Sotos et al., 2016)
reports on the relationship between NSAIDs and breast cancer in 1736 women with breast cancer
and 1895 healthy women. This study included all drugs indicated for the treatment of
inflammatory diseases including Aspirin, acetic acid derivatives (diclofenac and Toradol),
propionic acid derivatives (ibuprofen, naproxen) and Coxibs (celecoxib). The use of these drugs
was measured in the number of years taken with groups being split into those who had taken the
medication less than five years or five or more years. In this study there is a 24% reduction of
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breast cancer risk with the use of NSAIDs (Dierssen-Sotos et al., 2016). Additionally, there were
similar reductions with acetic acid derivatives, other propionic acid derivatives and Coxibs.
These results were not seen with aspirin. These results were noted in hormone + or HER 2 +
breast cancer (Dierssen-Sotos et al., 2016).
The California Teacher Study (Clarke et al., 2017) assessed the risk of breast cancer
development in a cohort of over 50,000 public school professionals in relation to their selfreported use of NSAIDs (Clarke et al., 2017). This study showed an inverse association with the
development of breast cancer in those who take three low dose aspirin tablets per week. Those
taking other types of NSAIDs had a marginal decrease noted. These outcomes were consistent
with other studies however this was the first study to look at low dose aspirin. Additionally, these
outcomes were only consistent in women with hormone receptor positive/ HER2 negative
cancers (Clarke et al., 2017).
Other studies have more thoroughly examined the link between genetics and breast
cancer and the possible influence of NSAIDs. One cohort study looked at a group of women
aged 18 to 71. Women either used aspirin, a COX-2 inhibitor, ibuprofen and other NSAIDs or
Acetaminophen at regular intervals. This study also took into consideration the risk associated
with familial history or breast cancer including BRCA1 and BRCA2 carriers (Kehm et al., 2019).
Findings showed 39% and 37% reduced risk of breast cancer in the prospective and combined
cohorts using Aspirin. Those using a COX-2 inhibitor show a 61% and 71% reduced risk of
developing breast cancer. Other NSAIDs and acetaminophen were not associated with any
reduced risk. Additionally, there was no alteration in risk associated with use of these
medications and the consideration of familial history or genetic factors (Kehm et al., 2019).
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A prospective study of women who have a sister with breast cancer assessed the use of
NSAIDs with their lifetime risk of developing cancer. When looking at the use of non-Coxib and
non-aspirin NSAIDs and their overall risk no evidence of reduction in post-menopausal women
(Kim et al., 2015). However, in premenopausal women there was a small but significant
reduction in the risk for breast cancer in those taking NSAIDs or Aspirin (Kim et al., 2015).
A systematic review looking at several large studies (Sutton et al., 2015), examined the
outcomes of women taking NSAIDs or aspirin after diagnosis with breast cancer. This review
examined a large body of literature regarding the mortality of women with breast cancer
following surgical intervention. The study looked at the use of NSAIDs in the treatment of these
women (Sutton et al., 2015). The studies did not reveal any significant reduction of mortality
related to breast cancer. However, it was noted that there was little data looking at specific
dosages and the specifics of the patients in question. This review highlighted the need for large,
randomized trials in looking more in depth at this topic (Sutton et al., 2015).
Data from two retrospective institutional studies (Desmedt et al., 2018) examined the use
of NSAIDs in the intraoperative period for primary cancer surgery related to the risk of
recurrence of the breast cancer. The patients involved in these studies were women considered
to have elevated body mass index (BMI) of greater than or equal to 25. During surgery the
patients were given either Toradol or diclofenac for pain control and to attempt to reduce the
amount of opioid pain medications used (Desmedt et al., 2018). With the used of diclofenac there
was no change in rates of cancer recurrence. In patients who received intraoperative Toradol
there was a clinically significant reduction in the rate of distant cancer recurrence (Desmedt et
al., 2018).
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Another population based, case-controlled study looking at just over 5,000 women
addresses the concern for inflammation causing increased rates of cancer (Cui et al., 2014). This
study found that there was a reduction in the risk of getting breast cancer in women taking
NSAIDs. The risk reduction was most notable when the individual was also taking a low dose
aspirin. Additionally, the risk reduction was more significant for overweight women (Cui et al.,
2014).
Two invitro studies (Bowers et al., 2014), which looked at the sera of breast cancer
patients analyzed the daily use of an NSAID that provides COX-2 inhibition. This study looked
at how the use of this medication can reduce the risk of recurrent estrogen positive breast cancer
in women specifically those who may be at an increased risk as a result of an increased BMI.
This retrospective study found that women with a BMI of 30 or more, taking an NSAID had a
52% less chance of having recurrent breast cancer with an additional 28 months noted before
recurrence. This study also examined the serology of normal weight women and those who are
overweight. These results show an increase risk of breast cancer in overweight women (Bowers
et al., 2014).
While there are promising studies that show a potential benefit in NSAID use correlating
to breast cancer risk reduction, there is not sufficient data available to recommend using NSAIDs
for the prevention of breast cancer at this time. More research is needed before making additional
conclusions about the use of NSAIDs in this way. These trials could assess dosage and have
specific parameters in place for the type of patient and breast cancer being assessed. It can also
be concluded that aspirin has also had mixed results in the prevention of breast cancer in certain
populations. These trials are needed to further demonstrate the efficacy of each drug, which
dosages should be given and to which type of patient.
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Learning Points
-

Modifiable risk factors should remain a priority for health care providers in reducing
breast cancer risk in women. These factors include physical activity and a sedentary
lifestyle, being overweight or obese, some forms of hormone replacement therapy when
used for over 5 years during or after menopause and drinking alcohol. Other reproductive
factors include not becoming pregnant until after age 30, not breast feeding and not
having a full term pregnancy. Providers should give adequate teaching in these topics and
provide resources as needed to support women who would like to pursue change in any
of these areas.

-

Current literature does not recommend using NSAIDs or aspirin to reduce the risk of
breast cancer. While some data does seem encouraging most of the existing data that
remains inconclusive. What we can conclude from the above information is that genetic
predisposition and obesity can increase a woman’s risk of developing breast
cancer. Additionally, the existing trials do not show specific data regarding which
NSAIDs and which dosages could be recommended for this use.

-

Further research is needed to determine if the use of an NSAID could be used to reduce
breast cancer risk. These studies need to be large and randomized. Additionally, they
should look at specific dosages of drugs on certain populations of women in order to
determine whether or not it is truly effective in reducing risk.
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